Last reviewed · How we verify
TS-1
TS-1 is an oral combination chemotherapy agent that inhibits thymidylate synthase and enhances fluorouracil activity against cancer cells.
TS-1 is an oral combination chemotherapy agent that inhibits thymidylate synthase and enhances fluorouracil activity against cancer cells. Used for Gastric cancer, Colorectal cancer, Non-small cell lung cancer.
At a glance
| Generic name | TS-1 |
|---|---|
| Also known as | S-1, Tegafur-gimeracil-oteracil potassium |
| Sponsor | National Health Research Institutes, Taiwan |
| Drug class | Antimetabolite chemotherapy combination |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TS-1 is a fixed-dose combination of tegafur (a prodrug of fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (a orotate phosphoribosyltransferase inhibitor). Gimeracil inhibits the degradation of fluorouracil, while oteracil reduces gastrointestinal toxicity by blocking its activation in the GI tract, allowing higher systemic exposure and improved efficacy.
Approved indications
- Gastric cancer
- Colorectal cancer
- Non-small cell lung cancer
Common side effects
- Bone marrow suppression (neutropenia, thrombocytopenia)
- Gastrointestinal toxicity (nausea, diarrhea)
- Hand-foot syndrome
- Fatigue
Key clinical trials
- Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma (PHASE1, PHASE2)
- NGS as the First-line Treatment in Advanced Biliary Tract Cancer (PHASE2)
- Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer (PHASE2, PHASE3)
- Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma (PHASE2)
- Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma (PHASE2)
- Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. (PHASE1)
- Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (PHASE3)
- Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TS-1 CI brief — competitive landscape report
- TS-1 updates RSS · CI watch RSS
- National Health Research Institutes, Taiwan portfolio CI